Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia

Vox Sanguinis

Volumn 103, Issue 1, 2012, Pages 18-24

  Beliaev, A M ^a   Marshall, R J ^b   Gordon, M ^a   Smith, W ^a   Windsor, J A ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Blood transfusion; Complications; Cost effectiveness; Jehovah's Witnesses; Mortality; Treatment refusal

Indexed keywords

HEMOGLOBIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; CHRONIC KIDNEY FAILURE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART ARRHYTHMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; JEHOVAH'S WITNESS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PALLIATIVE THERAPY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; JEHOVAH'S WITNESSES; MALE; MIDDLE AGED; TREATMENT REFUSAL;

EID: 84862338600     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01573.x     Document Type: Article

References (30)

1. Allain J-P: Transfusion risks of yesterday and of today. Transfus Clin Biol 2003; 10:1-5.
2. Regan F, Taylor C: Blood transfusion medicine. BMJ 2002; 325:143-147.
3. Vanderlinde ES, Heal JM, Blumberg N: Autologous transfusion. BMJ 2002; 324:772-775.
4. Dohnalek LJ, Cusaac L, Westcott J, et al.: The code to safer transfusions. Nurs Manage 2004; 35:33-36.
5. Jackson BR, Busch MP, Stramer SL, et al.: The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43:721-729.
6. Smith R: Doctors question whether all blood transfusions are effective and necessary. BMJ 2005; 7491:558.
7. Laupacis A: Alternatives to blood transfusion are risky too. CMAJ 1998; 159:137-138.
8. Napolitano LM: The most serious motivation for the development of a blood substitute is the worldwide shortage of safe and viable allogeneic donor blood. Preface. Crit Care Clin 2009; 25:xi-xii.
9. Cremieux PY, Finkelstein SN, Berndt ER, et al.: Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. PharmacoEconomics 1999; 16(5 Pt 1):459-472.
10. McClelland B, Contreras M: Appropriateness and safety of blood transfusion. BMJ 2005; 330:104-105.
11. National Centre for Classification in Health: The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), 3rd edn. Sydney, National Centre for Classification in Health, 2002.
12. Fox-Rushby J, Cairns J: The structure of economic evaluation; in Fox-Rushby J, Cairns J (eds): Economic Evaluation. Maidenhead, Open University Press, 2005: 5-64.
13. Napolitano LM, Kurek S, Luchette FA, et al.: Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. [Erratum appears in Crit Care Med 2010 Jul;38(7):1621]. Crit Care Med 2009; 37:3124-3157.
14. Murphy MF, Wallington TB, Kelsey P, et al.: British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the clinical use of red blood cell transfusions. Br J Haematol 2001; 113:24-31.
15. Pillonel J, Laperche S: Etablissement Français du sang. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005; 10:5-8.
16. Shander A, Hofmann A, Gombotz H, et al.: Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007; 21:271-289.
17. Tokin C, Almeda J, Jain S, et al.: Blood-management programs: a clinical and administrative model with program implementation strategies. Perm J 2009; 13:18-28.
18. Hill S, Carless P, Henry D, et al.: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Libr 2009; 1:1-39.
19. Zilberberg M, Shorr A: Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. BMC Health Serv Res 2007; 7:138.
20. Beliaev AM, Marshall RJ, Smith W, et al.: Mortality risk stratification in severely anaemic Jehovah's witness patients. Intern Med J 2011 (in press).
21. Zilberberg M, Stern Lee S, Wiederkehr DP, et al.: Anemia, transfusions and hospital outcomes among critically ill patients on prolonged acute mechanical ventilation: a retrospective cohort study. Crit Care 2008; 12:R60.
22. Scott BH, Seifert FC, Grimson R: Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth 2008; 11:15-19.
23. Linden JV, Wagner K, Voytovich AE, et al.: Transfusion errors in New York State: an analysis of 10years' experience. Transfusion 2000; 40:1207-1213.
24. Vamvakas EC, Blajchman MA: Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113:3406-3417.
25. Linden JV, Paul B, Dressler KP: A report of 104 transfusion errors in New York State. Transfusion 1992; 32:601-606.
26. Sazama K: Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30:583-590.
27. Gajic O, Moore SB: Transfusion-related acute lung injury. Mayo Clin Proc 2005; 80:766-770.
28. Shander A: Financial and clinical outcomes associated with surgical bleeding complications. Surgery 2007; 4(Suppl):S20-S25.
29. Sandler SG, Yu H, Rassai N: Risks of blood transfusion and their prevention. Clin Adv Hematol Oncol 2003; 1:307-313.
30. Seed CR, Kiely P, Keller AJ: Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005; 35:592-598.